Braintree, Buyers Settle Generic MiraLax Suit For $17M

Law360, Los Angeles (January 20, 2012, 7:16 PM EST) -- Drug buyer plaintiffs in a putative antitrust class action accusing Braintree Laboratories Inc. of initiating baseless patent litigation to block a generic version of the laxative MiraLax asked a Delaware federal judge Friday to approve a $17.25 million settlement of direct purchaser claims.

Rochester Drug Cooperative Inc., Louisiana Wholesale Drug Co. and Meijer Inc. — which bought MiraLax directly from Braintree at what they claim was an inflated cost — filed a motion Friday asking U.S. District Judge Sue L. Robinson to certify a class of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.